Accordingly, the FAP-HCAs in our collective lack signs for an increased risk of malignant transformation, which in contrast is the case for beta-catenin-activated HCA, and there is only a single case report on a FAP-HCA with malignant transformation in the literature [25]. The gene discussed is FAP; the disease is hepatocellular adenoma.